Developing 21st Century Medicines
Leading Innovation and Developing Tomorrow’s Medicines™
Developing 21st century genetic medicines requires bold vision and groundbreaking science. At SMDG, we are developing tomorrow’s medicines through proprietary peptide-based therapeutic platforms designed to enable precision delivery of next-generation therapies. Our technologies are being developed to address significant unmet medical needs across rare pediatric, neurodegenerative and inflammatory diseases.
Learn more about our mission and vision.
You can find further details regarding our work in the journals and publications where our research has been featured and recognized
Inspired by Nature, Engineered to Heal
Inspired by nature, we engineer the next generation of targeted precision therapeutics. Our proprietary peptide-based NanoLigand™ platforms harness first-in-class receptor-mediated delivery and self-assembling nanotechnology to overcome biological barriers and enable precise delivery of therapeutic payloads, including genetic medicines, to challenging tissues. Our pioneering research has helped advance the understanding of biological barriers and inspired the development of potentially safer, more precise medicines. Through our Safe-by-Design and Simple-by-Design approach, we are creating first-in-class potentially disease-modifying therapies to transform the lives of patients.
Pioneering Research
Our Chief Science Officer and inventor of our platforms
Professor Moein Moghimi is a globally recognized pioneer in nanomedicine, drug delivery, and engineering biology. For decades, his research has advanced the understanding of nanocarrier design, biological interactions, complement biology and precision delivery, laying the foundations for safer and more effective therapeutic technologies. His pioneering work has inspired SMDG’s proprietary peptide-based platforms, designed to enable targeted delivery of next-generation medicines and transform the treatment of diseases with significant unmet medical needs.
